AEON Biopharma announces strategic reprioritization for ABP-450 (NYSE:AEON)

  • AEON Biopharma (NYSE:AEON) on Tuesday said that it had announced plans to advance a single clinical development study in cervical dystonia for ABP-450 injection, utilizing the 351(k) regulatory pathway for biosimilars with BOTOX ((onabotulinumtoxinA)) as the reference product.
  • The company